Former FDA Director Peter Marks Resigns, Joins Eli Lilly
Peter Marks, the former director of the US FDA's Center for Biologics Evaluation and Research, has resigned from the agency. Marks, who played a crucial role in establishing Operation Warp Speed, left the FDA in March 2023. In his resignation letter, he criticized RFK Jr.'s views on vaccines and his lack of support for truth and transparency.
Marks' resignation came after pressure from HHS Secretary Robert F. Kennedy Jr. Prior to his role at the FDA, Marks served as deputy director and later director of the CBER from 2012 to 2023. Despite his departure from the FDA, Marks has not been idle. He has joined Eli Lilly (NYSE:LLY) as SVP, molecule discovery, and head of infectious diseases. The exact date of Marks' employment at Eli Lilly is not specified in the search results.
Marks' resignation from the FDA and subsequent move to Eli Lilly mark significant changes in the biopharmaceutical industry. His expertise in vaccine development and infectious diseases will be valuable to Eli Lilly. Meanwhile, his criticism of RFK Jr.'s views on vaccines highlights the ongoing debate surrounding vaccine policies.
Read also:
- Trump's SNAP reductions and New York City Council's grocery delivery legislation: Problems for city residents highlighted
- Reducing dental expenses for elderlies in Sweden: Over 50% cut in charges for pensioners by the government
- Forty-year-old diet: A list of meal choices to savor
- Exiled Life's Conundrum: A Blend of Liberation, Disillusionment, and Distress
